News

Surfaxin (lucinactant intratracheal suspension) is a synthetic, peptide-containing surfactant, indicated for use in premature infants at high risk for RDS. Discovery Labs chief executive officer and chairman of

Amitiza is indicated for the treatment of chronic idiopathic constipation and for IBS-C. The open-label extension Phase 3 study was conducted by Takeda Pharmaceuticals USA, and Sucampo Pharmaceuticals

The LyoCell technology allows for the solubilization, stabilization, and delivery of a wide range of compounds – both small and large molecule. As per the agreement, PSI obtains

Marshall Edwards is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. Marshall Edwards president and chief executive officer Daniel Gold expressed satisfaction

The new product called Diabetic Vision Formula was developed to help protect against potential vision problems associated with diabetic retinopathy, a condition that may lead to blindness and

The application was not approved by FDA because the pre-specified analysis of the primary endpoint in the study (DACO-016) did not demonstrate statistically significant superiority of Dacogen over

CK-2017357, the lead drug candidate that has emerged from the Cytokinetics’ skeletal sarcomere activator program, is currently the subject of an ongoing Phase II clinical development program in

The prospectively designed, head-to-head clinical trials will provide important information to physicians, patients, caregivers, and payors to make informed choices, said the company. Shire Specialty Pharmaceuticals and Regenerative

As per the agreement, the companies aim to develop and commercialize at least three new vaccines with MTPC who will provide funding for all research and development costs.